Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 9%

Bulls say

Arvinas is expected to generate positive clinical data in the next 12-18 months, providing potential upside for investors. With a strong pipeline targeting oncology and neuroscience indications, partnerships with large pharmaceutical companies, and a solid cash position, Arvinas has the potential for significant future growth and success. The company's market cap is currently hovering around $4.5 billion, with a cash runway into the second half of 2028, providing investors with a favorable entry point and potential for a meaningful return on investment.

Bears say

Arvinas is a clinical-stage biotechnology company using its PROteolysis TArgeting Chimera platform to develop therapies targeting disease-causing proteins. Despite promising preclinical data, concerns remain about the effectiveness and tolerability of its lead candidate ARV-806 compared to competitors and potential resistance mechanisms. The company also faces typical risks associated with the biotech industry, including clinical and regulatory uncertainties and competition. Additionally, while Arvinas has a strong pipeline with potential in several disease areas, its valuation may be considered high compared to its current stage of development.

Arvinas Inc (ARVN) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 11 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.